US 12,325,755 B2
Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics
Bin Liu, San Francisco, CA (US); Yang Su, South San Francisco, CA (US); Scott Bidlingmaier, San Francisco, CA (US); Christopher R. Behrens, San Francisco, CA (US); and Namkyung Lee, San Francisco, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Nov. 21, 2019, as Appl. No. 16/691,417.
Application 16/691,417 is a continuation of application No. 15/508,059, granted, now 10,533,056, previously published as PCT/US2015/049492, filed on Sep. 10, 2015.
Claims priority of provisional application 62/049,973, filed on Sep. 12, 2014.
Prior Publication US 2020/0199245 A1, Jun. 25, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 31/7088 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61K 51/10 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/2896 (2013.01) [A61K 31/7088 (2013.01); A61K 47/6811 (2017.08); A61K 47/6817 (2017.08); A61K 47/6849 (2017.08); A61K 47/6869 (2017.08); A61K 51/1027 (2013.01); C07K 16/30 (2013.01); C07K 16/3069 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/30 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/77 (2013.01); G01N 2333/70596 (2013.01); Y02A 50/30 (2018.01)] 43 Claims
 
1. An isolated recombinant human antibody that specifically binds CD46 comprising VH CDR1 comprising the amino acid sequence of SEQ ID NO. 80, VH CDR2 comprising the amino acid sequence of SEQ ID NO. 82, VH CDR3 comprising the amino acid sequence of SEQ ID NO. 84, VL CDR1 comprising the amino acid sequence of SEQ ID NO. 227, VL CDR2 comprising the amino acid sequence of SEQ ID NO. 229, and VL CDR3 comprising the amino acid sequence of SEQ ID NO. 231.